基于腺相关病毒载体血清型9的基因治疗用于A型尼曼-匹克病
研究评估了小脑延髓池注射编码人酸性鞘磷脂酶的腺相关病毒血清型9载体在非人灵长类中的安全性,并在ASM基因敲除小鼠模型中评估了治疗获益。非人灵长类中注射后脑和脊髓细胞广泛表达转基因且无毒性迹象;小鼠中注射后脑脊液和不同脑区表达人酸性鞘磷脂酶且未触发炎症反应,并确定了小鼠小脑延髓池注射的最小有效治疗剂量。给药两个月后,治疗防止了ASM基因敲除小鼠的运动和记忆障碍、鞘磷脂积累、溶酶体增大和神经元死亡。
要点
- 非人灵长类小脑延髓池注射AAV9-hASM后脑和脊髓细胞广泛表达转基因且无毒性迹象。
- ASM基因敲除小鼠小脑延髓池注射后脑脊液和不同脑区表达hASM且未触发炎症反应。
- 小鼠给药两个月后治疗防止运动和记忆障碍、鞘磷脂积累、溶酶体增大和神经元死亡。
核心结论
- 结果支持小脑延髓池注射用于未来A型尼曼-匹克病及其他溶酶体贮积性脑病的AAV9-based临床试验。
研究设计与样本
- 在非人灵长类中评估小脑延髓池注射编码人酸性鞘磷脂酶的腺相关病毒血清型9载体的安全性。
- 在ASM基因敲除小鼠模型中评估小脑延髓池注射AAV9-hASM的治疗获益。
主要发现
- 非人灵长类小脑延髓池注射后脑和脊髓细胞广泛表达转基因且无毒性迹象。
- ASM基因敲除小鼠小脑延髓池注射后脑脊液和不同脑区表达hASM且未触发炎症反应,而直接小脑注射AAV9-hASM触发了免疫反应。
- 鉴定了小鼠小脑延髓池注射AAV9-hASM的最小有效治疗剂量。
- 给药两个月后,治疗防止了ASM基因敲除小鼠的运动和记忆障碍、鞘磷脂积累、溶酶体增大和神经元死亡。
- 小脑延髓池注射AAV9-hASM的ASM基因敲除小鼠血浆中检测到ASM活性,同时肝脏鞘磷脂量减少和炎症减轻。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Niemann-Pick disease type A (NPD-A) is a lysosomal storage disorder characterized by neurodegeneration and early death. It is caused by loss-of-function mutations in the gene encoding for acid sphingomyelinase (ASM), which hydrolyzes sphingomyelin into ceramide. Here, we evaluated the safety of cerebellomedullary (CM) cistern injection of adeno-associated viral vector serotype 9 encoding human ASM (AAV9-hASM) in nonhuman primates (NHP). We also evaluated its therapeutic benefit in a mouse model of the disease (ASM-KO mice). We found that CM injection in NHP resulted in widespread transgene expression within brain and spinal cord cells without signs of toxicity. CM injection in the ASM-KO mouse model resulted in hASM expression in cerebrospinal fluid and in different brain areas without triggering an inflammatory response. In contrast, direct cerebellar injection of AAV9-hASM triggered immune response. We also identified a minimally effective therapeutic dose for CM injection of AAV9-hASM in mice. Two months after administration, the treatment prevented motor and memory impairment, sphingomyelin (SM) accumulation, lysosomal enlargement, and neuronal death in ASM-KO mice. ASM activity was also detected in plasma from AAV9-hASM CM-injected ASM-KO mice, along with reduced SM amount and decreased inflammation in the liver. Our results support CM injection for future AAV9-based clinical trials in NPD-A as well as other lysosomal storage brain disorders.
引用
- Samaranch L, Pérez-Cañamás A, Soto-Huelin B, et al. Adeno-associated viral vector serotype 9-based gene therapy for Niemann-Pick disease type A. Sci Transl Med. 2019. PMID: 31434754. doi:10.1126/scitranslmed.aat3738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。